Last reviewed · How we verify
Intravenous scopolamine hydrobromide
Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.
Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea. Used for Prevention of nausea and vomiting associated with motion sickness, Prevention of postoperative nausea and vomiting, Reduction of salivary and bronchial secretions during anesthesia.
At a glance
| Generic name | Intravenous scopolamine hydrobromide |
|---|---|
| Sponsor | University of Iowa |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Perioperative Medicine |
| Phase | FDA-approved |
Mechanism of action
Scopolamine competitively antagonizes acetylcholine at muscarinic receptors in the central and peripheral nervous system. This anticholinergic activity reduces gastric secretions, decreases smooth muscle contractions in the GI tract, and depresses the vomiting center and vestibular apparatus in the brain, making it effective for preventing nausea and vomiting associated with motion sickness and postoperative states.
Approved indications
- Prevention of nausea and vomiting associated with motion sickness
- Prevention of postoperative nausea and vomiting
- Preoperative medication to reduce secretions
Common side effects
- Dry mouth
- Drowsiness
- Blurred vision
- Dizziness
- Tachycardia
- Urinary retention
Key clinical trials
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers (PHASE1, PHASE2)
- SAINT: Safe Induction of Labor Trial (PHASE3)
- Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy (PHASE4)
- Comparison of LCBDE vs ERCP + LC for Choledocholithiasis (NA)
- BUSCLAB - Buscopan to Prevent Slow Progress in Labor (PHASE3)
- The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae (PHASE4)
- Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women (PHASE4)
- Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous scopolamine hydrobromide CI brief — competitive landscape report
- Intravenous scopolamine hydrobromide updates RSS · CI watch RSS
- University of Iowa portfolio CI